Results 21 to 30 of about 26,349 (219)
Frontiers in Cardiovascular Medicine, 2021 Cardiomyopathy often leads to dilated cardiomyopathy (DCM) when caused by viral myocarditis. Apoptosis is long considered as the principal process of cell death in cardiomyocytes, but programmed necrosis or necroptosis is recently believed to play an ...
Yujing Wu +12 more
doaj +1 more source
Cardiomyocyte Overexpression of FABP4 Aggravates Pressure Overload-Induced Heart Hypertrophy. [PDF]
PLoS ONE, 2016 Fatty acid binding protein 4 (FABP4) is a member of the intracellular lipid-binding protein family, responsible for the transportation of fatty acids.
Ji Zhang +7 more
doaj +1 more source
Long-Term Follow-Up After Discontinuation of Mavacamten in Hypertrophic Obstructive CardiomyopathyNovel Teaching Points [PDF]
CJC OpenMengdi Yu, BMSc +4 more
doaj +2 more sources
Efficacy and Safety of Selective Cardiac Myosin Inhibitors in the Treatment of Hypertrophic Cardiomyopathy: a Meta-analysis [PDF]
Zhongguo quanke yixueBackground Hypertrophic cardiomyopathy (HCM) is a genetic disorder, characterized primarily by left ventricular outflow tract obstruction and asymmetric myocardial hypertrophy, which predisposes to sudden cardiac death and malignant arrhythmias. Although
ZHANG Huijuan, LI Xinghui, ZHANG Xiaoming, YIN Long, SHAO Long
doaj +1 more source
Aldosterone inhibits the fetal program and increases hypertrophy in the heart of hypertensive mice. [PDF]
PLoS ONE, 2012 BACKGROUND: Arterial hypertension (AH) induces cardiac hypertrophy and reactivation of "fetal" gene expression. In rodent heart, alpha-Myosin Heavy Chain (MyHC) and its micro-RNA miR-208a regulate the expression of beta-MyHC and of its intronic miR-208b.
Feriel Azibani +12 more
doaj +1 more source
Pinocembrin Protects Cardiomyocytes Against Isoproterenol-Induced Hypertrophy
Natural Product Communications, 2021 Cardiac hypertrophy is characterized by an increase in myocardial cell volume and extracellular matrix production. Persistent cardiac hypertrophy can cause dilated cardiomyopathy, heart failure, and even death.
Xin Sui +7 more
doaj +1 more source
Future Science OA, 2023 Aim: This meta-analysis was performed to assess the efficacy and safety of mavacamten in patients with hypertrophic cardiomyopathy. Methods & materials: A search was conducted using PubMed, Cochrane, and Scopus up to August 2022 for randomized studies ...
Areeba Memon +9 more
doaj +1 more source
Cardiac myosin inhibitors in hypertrophic cardiomyopathy
Journal of Cardiovascular ImagingAbstract Mavacamten, the first selective and reversible cardiac myosin inhibitor (CMI), has been introduced to the clinical arena for the treatment of obstructive hypertrophic cardiomyopathy (HCM). By reducing excessive actin-myosin cross-bridging, this agent decreases myocardial contractility and alleviates the dynamic left ventricular ...
Lim, Jaehyun, Kim, Hyung-Kwan
openaire +2 more sources
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2022 Background Heart failure, caused by sustained pressure overload, remains a major public health problem. PKM (pyruvate kinase M) acts as a rate‐limiting enzyme of glycolysis. PKM2 (pyruvate kinase M2), an alternative splicing product of PKM, plays complex
Le Ni +7 more
doaj +1 more source
Open HeartBackground Unlike other suggested therapies, myosin inhibitors have been shown to change the course of hypertrophic cardiomyopathy by altering the contractile mechanics of cardiomyocytes.
Ayesha Aman +7 more
doaj +1 more source